Literature DB >> 33316872

Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems.

Patrícia de Faria Lainetti1, Antonio Fernando Leis-Filho1, Renee Laufer-Amorim2, Alexandre Battazza3, Carlos Eduardo Fonseca-Alves1,4.   

Abstract

Breast cancer (BC) is one of the most important cancers worldwide, and usually, chemotherapy can be used in an integrative approach. Usually, chemotherapy treatment is performed in association with surgery, radiation or hormone therapy, providing an increased outcome to patients. However, tumors can develop resistance to different drugs, progressing for a more aggressive phenotype. In this scenario, the use of nanocarriers could help to defeat tumor cell resistance, providing a new therapeutic perspective for patients. Thus, this systematic review aims to bring the molecular mechanisms involved in BC chemoresistance and extract from the previous literature information regarding the use of nanoparticles as potential treatment for chemoresistant breast cancer.

Entities:  

Keywords:  liposomal nanostructures; neoadjuvant therapy; siRNA nanoparticles; treatment resistance

Year:  2020        PMID: 33316872     DOI: 10.3390/pharmaceutics12121193

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  11 in total

1.  Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Qixing Tan; Qinghong Qin; Zhen Huang; Bin Lian; Qinguo Mo; Changyuan Wei
Journal:  Breast Cancer Res Treat       Date:  2022-03-18       Impact factor: 4.872

2.  The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer.

Authors:  Shogo Nakamoto; Masahiko Ikeda; Shinichiro Kubo; Mari Yamamoto; Tetsumasa Yamashita; Chihiro Kuwahara
Journal:  Cancer Diagn Progn       Date:  2021-11-03

3.  A Novel YTHDF3-Based Model to Predict Prognosis and Therapeutic Response in Breast Cancer.

Authors:  Jie Liu; Jing Zhu; Xin Wang; Zhisheng Zhou; Haiyan Liu; Dajiang Zhu
Journal:  Front Mol Biosci       Date:  2022-06-09

Review 4.  The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword.

Authors:  Mohammad Heydarian; Mohammadjavad Mohammadtaghizadeh; Mahboobeh Shojaei; Marziyeh Babazadeh; Sadegh Abbasian; Mehran Amrovani
Journal:  Mol Biol Rep       Date:  2021-10-16       Impact factor: 2.742

5.  MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer.

Authors:  Diana E Baxter; Lisa M Allinson; Waleed S Al Amri; James A Poulter; Arindam Pramanik; James L Thorne; Eldo T Verghese; Thomas A Hughes
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

6.  P-Glycoprotein and Androgen Receptor Expression Reveals Independence of Canine Prostate Cancer from Androgen Hormone Stimulation.

Authors:  Alexandre Matheus Baesso Cavalca; Andressa Brandi; Ricardo Henrique Fonseca-Alves; Renée Laufer-Amorim; Carlos Eduardo Fonseca-Alves
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

Review 7.  'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.

Authors:  Sabba Mehmood; Muhammad Faheem; Hammad Ismail; Syeda Mehpara Farhat; Mahwish Ali; Sidra Younis; Muhammad Nadeem Asghar
Journal:  Front Mol Biosci       Date:  2022-04-14

8.  The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats.

Authors:  Sri Susilowati; Hermawan Istiadi; Suhartono Suhartono; Yan Wisnu Prajoko; Ignatius Riwanto; Neni Susilaningsih; Catharina Suharti
Journal:  Asian Pac J Cancer Prev       Date:  2022-03-01

9.  Attenuated Microcirculation in Small Metastatic Tumors in Murine Liver.

Authors:  Arturas Ziemys; Vladimir Simic; Miljan Milosevic; Milos Kojic; Yan Ting Liu; Kenji Yokoi
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

10.  Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.

Authors:  Shogo Nakamoto; Junichiro Watanabe; Shoichiro Ohtani; Satoshi Morita; Masahiko Ikeda
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.